1198174-48-9Relevant articles and documents
Development of novel azabenzofuran TRPA1 antagonists as in vivo tools
Copeland, Katrina W.,Boezio, Alessandro A.,Cheung, Eugene,Lee, Josie,Olivieri, Philip,Schenkel, Laurie B.,Wan, Qian,Wang, Weiya,Wells, Mary C.,Youngblood, Beth,Gavva, Narender R.,Lehto, Sonya G.,Geuns-Meyer, Stephanie
supporting information, p. 3464 - 3468 (2014/07/22)
The transient receptor potential ankyrin 1 (TRPA1) channel is activated by noxious stimuli including chemical irritants and endogenous inflammatory mediators. Antagonists of this channel are currently being investigated for use as therapeutic agents for t
Tricyclic 3,4-dihydropyrimidine-2-thione derivatives as potent TRPA1 antagonists
Gijsen, Harrie J.M.,Berthelot, Didier,De Cleyn, Michel A.J.,Geuens, Ivo,Brone, Bert,Mercken, Marc
supporting information; experimental part, p. 797 - 800 (2012/03/11)
The transient receptor potential A1 (TRPA1) channel has been implicated in a number of inflammatory and nociceptive processes, and antagonists of the TRPA1 receptor could offer a potential treatment for conditions such as inflammatory or neuropathic pain,
3,4-DIHYDROPYRIMIDINE TRPA1 ANTAGONISTS
-
Page/Page column 27, (2009/12/28)
The present invention is related to novel 3,4-dihydropyrimidine compounds of formula (I) having TRPA1 receptor antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use